Beto Financial Group LLC Makes New $1.03 Million Investment in Johnson & Johnson $JNJ

Key Points

• Beto Financial Group LLC opened a new position in Johnson & Johnson in the fourth quarter, buying 4,968 shares valued at about $1.03 million. The stake now makes JNJ the firm’s 29th largest holding.
• Several other institutional investors also added to or adjusted J&J holdings, and institutional ownership remains high at 69.55% of the company’s stock.
• Analysts remain broadly positive: the stock has a consensus rating of “Moderate Buy” with an average price target of $253.04, while J&J recently beat quarterly EPS and revenue estimates and raised its quarterly dividend to $1.34 per share.

Beto Financial Group LLC bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,968 shares of the company's stock, valued at approximately $1,028,000. Johnson & Johnson comprises about 0.7% of Beto Financial Group LLC's portfolio, making the stock its 29th largest position.

Several other institutional investors also recently modified their holdings of JNJ. Plancorp LLC boosted its holdings in shares of Johnson & Johnson by 0.3% in the fourth quarter. Plancorp LLC now owns 15,889 shares of the company's stock valued at $3,288,000 after buying an additional 45 shares during the period. Baron Silver Stevens Financial Advisors LLC grew its position in shares of Johnson & Johnson by 0.8% in the fourth quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company's stock valued at $1,168,000 after purchasing an additional 45 shares during the last quarter. Strategic Financial Services Inc. grew its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Strategic Financial Services Inc. now owns 8,995 shares of the company's stock valued at $1,862,000 after purchasing an additional 45 shares during the last quarter. WealthCollab LLC boosted its stake in Johnson & Johnson by 4.7% in the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company's stock valued at $210,000 after purchasing an additional 46 shares during the period. Finally, MMA Asset Management LLC boosted its stake in Johnson & Johnson by 1.3% in the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company's stock valued at $745,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an "overweight" rating in a report on Wednesday, April 15th. Daiwa Securities Group lifted their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a report on Thursday, April 16th. Weiss Ratings lowered shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b)" rating in a report on Friday, April 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Stock Performance

JNJ opened at $223.90 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The company's fifty day moving average price is $232.75 and its two-hundred day moving average price is $225.29. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The company has a market cap of $538.96 billion, a price-to-earnings ratio of 25.88, a PEG ratio of 2.21 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the company posted $2.77 earnings per share. The business's revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio (DPR) is 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced strong late-stage prostate cancer data for ERLEADA (apalutamide), showing it significantly reduced the risk of metastasis or death and improved key surgical outcomes. The results, presented at ASCO and published in The New England Journal of Medicine, could strengthen the drug’s commercial outlook. Article Title
• Positive Sentiment: J&J also reported pivotal data for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in advanced head and neck cancer, with durable responses and a meaningful complete-response rate. The company has already submitted for FDA approval in this indication, which could expand its oncology pipeline. Article Title
• Positive Sentiment: Separate coverage highlighted Johnson & Johnson as one of the best dividend-paying stocks to buy right now, reinforcing its appeal as a defensive income name for investors seeking stability and yield. Article Title
• Neutral Sentiment: Another article asked whether J&J is too expensive after its 48% one-year surge, reflecting valuation concerns rather than a direct change in fundamentals. The piece suggests some investors may be pausing after the stock’s strong rally. Article Title
• Negative Sentiment: Recent commentary also noted the stock has slipped in the short term, implying some near-term profit-taking as investors digest the large year-to-date move and weigh whether upside is already reflected in the price. Article Title

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.